Rather & Kittrell’s AstraZeneca AZN Stock Holding History

Rather & Kittrell’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-635	Closed	-$73K	–	81
2021 Q4	$73K	Buy	+635	New	+$74.7K	0.06%	108

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Rather & Kittrell's AZN Position: Q1 2022 in Review

Rather & Kittrell sold out of AstraZeneca (AZN) in Q1 2022, closing a stake of 635 shares — an estimated $73K sold.

Rather & Kittrell first reported a position in AZN in Q4 2021 and held it in 1 quarter. The position peaked at $73K in Q4 2021. 982 funds tracked by Wall St. Rank hold AZN as of Q1 2022.

Rather & Kittrell reported no remaining AstraZeneca position as of Q1 2022 after selling out during the quarter.
Rather & Kittrell sold 635 AstraZeneca shares in Q1 2022, an estimated $73K.
Rather & Kittrell first reported a position in AstraZeneca in Q4 2021 and held it in 1 quarter.
Rather & Kittrell's AstraZeneca position peaked at $73K in Q4 2021.
982 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2022.

Based on Rather & Kittrell's 13F filing for Q1 2022, filed 10 May 2022.